United States Drug Patent 7,473,761: Scope, Claims, and Landscape Analysis
United States Patent 7,473,761, granted on January 6, 2009, to Wyeth Holdings Corporation (now a subsidiary of Pfizer Inc.), covers methods of treating and preventing neurological and psychiatric disorders by administering certain serotonin 2A (5-HT2A) receptor antagonists. The patent's claims focus on the use of specific chemical compounds exhibiting antagonist activity at the 5-HT2A receptor, primarily aimed at disorders where this receptor is implicated in pathophysiology. The patent landscape for this class of compounds is complex, with significant activity in both research and development and subsequent patent filings by numerous entities.
What Are the Key Inventions Covered by Patent 7,473,761?
The core invention protected by Patent 7,473,761 lies in the therapeutic application of a defined class of chemical compounds. While the patent does not claim the compounds themselves, it claims specific methods of using these compounds for therapeutic purposes. These methods target neurological and psychiatric conditions.
What Specific Therapeutic Methods Are Claimed?
The patent claims methods that involve administering a therapeutically effective amount of a compound that is a 5-HT2A receptor antagonist to a subject in need thereof. The primary indications and conditions addressed include:
- Treatment of anxiety disorders: This encompasses various forms of anxiety, including generalized anxiety disorder and panic disorder.
- Treatment of depressive disorders: This includes major depressive disorder and other depressive conditions where serotonin receptor modulation is considered beneficial.
- Treatment of sleep disorders: The patent notes the utility of these antagonists in managing sleep disturbances, potentially related to their effects on the central nervous system.
- Prevention of neurological and psychiatric disorders: Beyond treatment, the claims extend to prophylactic use, suggesting the compounds can be used to prevent the onset or recurrence of these conditions.
The patent defines a broad class of 5-HT2A receptor antagonists, allowing for a range of chemical structures to fall within its scope, provided they meet the functional criteria of antagonist activity.
What is the Mechanism of Action Relevant to These Claims?
The claims are predicated on the antagonistic activity at the serotonin 2A (5-HT2A) receptor. This receptor is a G protein-coupled receptor that plays a significant role in modulating various physiological and behavioral processes, including mood, anxiety, sleep, cognition, and perception. By blocking or reducing the activity of the 5-HT2A receptor, the claimed compounds are intended to alleviate symptoms associated with disorders where dysregulation of this receptor system is believed to contribute to the pathology.
The scientific rationale behind targeting the 5-HT2A receptor for these indications is supported by extensive preclinical and clinical research demonstrating its involvement in the neurobiology of mood and anxiety disorders [1]. Antagonism at this receptor can lead to downstream effects, such as increased dopamine release in certain brain regions, which is thought to contribute to antidepressant and anxiolytic effects [2].
What Are the Specific Chemical Definitions and Exclusions in the Patent?
Patent 7,473,761 defines a genus of compounds through a Markush structure. This structure outlines a core chemical framework with various substituents, allowing for a broad interpretation of claimed compounds. However, the patent also includes specific exclusions, narrowing the scope to avoid overlapping with existing patents or prior art.
What are the Structural Features of the Claimed Compounds?
The claims of Patent 7,473,761 define compounds that are substituted arylpiperidines and related heterocyclic compounds. A representative Markush structure is provided within the patent specification to delineate the claimed chemical space. This structure typically involves a core heterocyclic system, often a piperidine ring, attached to an aryl moiety. Various positions on these rings are substituted with functional groups that confer the desired binding affinity and antagonist activity at the 5-HT2A receptor.
Specific examples of compounds are listed within the patent, illustrating the types of chemical entities that embody the claimed invention. These examples often include detailed chemical names and structural representations. For instance, compounds with a general formula:
R1-aryl-X-Y-piperidine-R2
where R1, R2, X, and Y represent various chemical groups or linkages, are central to the patent's scope. The specific substituents are critical for defining the precise chemical boundaries of the claims.
Are There Any Explicit Exclusions or Limitations?
Yes, the patent includes explicit limitations and exclusions designed to refine the scope of the claims. These exclusions are crucial for understanding the patent's boundaries and identifying potential areas of freedom to operate for competitors.
Key exclusions often relate to:
- Prior art compounds: Compounds that were previously disclosed or patented and are known to possess 5-HT2A antagonist activity might be explicitly excluded to avoid invalidating the patent based on novelty or obviousness.
- Specific structural modifications: Certain modifications or substitutions that lead to compounds with different pharmacological profiles (e.g., agonists or partial agonists at the 5-HT2A receptor, or activity at other receptors) may be excluded.
- Compounds with known side effects: While not always explicit in structural definitions, the intent of the patent is to claim compounds that are therapeutically useful, implying a favorable safety and efficacy profile.
The precise scope of exclusion is determined by careful examination of the patent's claims, particularly any dependent claims or specific language used to limit the generic definitions.
What is the Commercial and Scientific Significance of the Patent's Claims?
Patent 7,473,761 addresses therapeutic targets that represent substantial markets in the pharmaceutical industry. The focus on anxiety, depression, and sleep disorders indicates a strategy to address conditions with high prevalence and unmet medical needs.
What Are the Major Therapeutic Areas Addressed?
The patent's claims directly impact the development of treatments for:
- Anxiety Disorders: These disorders are among the most common mental illnesses, affecting millions globally. The market for anxiolytics is substantial, with a continuous demand for novel agents offering improved efficacy and safety profiles.
- Depressive Disorders: Depression is a leading cause of disability worldwide. The development of new antidepressants with faster onset of action and reduced side effects remains a critical area of research and commercial interest.
- Sleep Disorders: Insomnia and other sleep disturbances are prevalent and often co-occur with psychiatric conditions. The market for sleep aids is significant, though it faces regulatory scrutiny due to concerns about dependence and side effects.
The broad scope of neurological and psychiatric disorders covered suggests an ambition to establish a wide therapeutic footprint for the claimed class of compounds.
How Does This Patent Fit into the Broader 5-HT2A Antagonist Landscape?
The 5-HT2A receptor has been a target for drug development for decades, leading to a complex patent landscape. Several established drugs and numerous investigational compounds target this receptor, often with varying selectivity profiles for different serotonin receptor subtypes.
Key considerations for Patent 7,473,761 within this landscape include:
- First-generation 5-HT2A antagonists: Drugs like trazodone and nefazodone, while having some 5-HT2A antagonist activity, are primarily known for their broader pharmacological profiles and are not exclusively defined by potent 5-HT2A antagonism.
- Selective 5-HT2A antagonists: The patent likely aims to protect compounds with a higher degree of selectivity for the 5-HT2A receptor, potentially offering a cleaner pharmacological profile with fewer off-target side effects.
- Therapeutic indications: While many 5-HT2A antagonists have been explored for various psychiatric conditions, Patent 7,473,761 carves out specific methods of treatment for a defined set of disorders.
The patent's strength lies in defining specific therapeutic methods for a class of compounds that may offer advantages over existing treatments or earlier generations of 5-HT2A modulators.
What is the Patent Landscape for 5-HT2A Receptor Antagonists?
The patent landscape surrounding 5-HT2A receptor antagonists is dynamic and characterized by numerous filings from pharmaceutical companies, academic institutions, and smaller biotechnology firms. This indicates a highly competitive research environment.
Who Are the Major Players in This Patent Landscape?
Several major pharmaceutical companies and numerous research institutions hold patents related to 5-HT2A receptor modulators. Key entities include:
- Pfizer Inc. (formerly Wyeth): As the assignee of Patent 7,473,761, Pfizer is a significant player. Their research has likely focused on developing novel compounds and methods of use for conditions involving the 5-HT2A pathway.
- Other Major Pharmaceutical Companies: Companies such as Eli Lilly and Company, Bristol-Myers Squibb, Merck & Co., and Johnson & Johnson have historically invested heavily in neuroscience and have active patent portfolios covering serotonin receptor modulators.
- Biotechnology Companies: Smaller firms specializing in drug discovery for neurological and psychiatric disorders also contribute to the patent landscape, often focusing on specific subtypes of serotonin receptors or novel mechanisms of action.
- Academic Institutions: Universities and research centers frequently file patents on novel compounds and therapeutic applications discovered through basic research, which are then licensed to commercial entities.
The presence of these diverse entities underscores the breadth of interest and investment in this therapeutic area.
How Does Patent 7,473,761 Compare to Other Relevant Patents?
Patent 7,473,761 is one of many patents that contribute to the overall intellectual property surrounding 5-HT2A receptor antagonists. Its specific contribution lies in the method of use claims for treating a defined set of neurological and psychiatric disorders.
Comparisons with other patents would involve analyzing:
- Scope of Claims: Some patents may claim specific novel compounds, while others claim new formulations, manufacturing processes, or different therapeutic indications for known compounds. Patent 7,473,761 focuses on method of use.
- Chemical Scope: The Markush structures and specific compound definitions in various patents will differ, defining distinct chemical spaces and potential overlaps.
- Therapeutic Indications: While Patent 7,473,761 covers anxiety, depression, and sleep disorders, other patents might focus on psychosis, cognitive impairment, pain, or other conditions where 5-HT2A receptor modulation is relevant.
- Patent Expiration Dates: The expiration dates of relevant patents determine when compounds and methods may enter the public domain, influencing generic competition and market exclusivity. Patent 7,473,761 is expected to expire in 2027 (20 years from the filing date of 2007, with potential for patent term extension).
Table 1: Comparison of Patent Focus in 5-HT2A Antagonist Landscape
| Patent |
Primary Focus |
Key Therapeutic Areas |
| US Patent 7,473,761 (Wyeth) |
Method of Use |
Anxiety, Depression, Sleep Disorders |
| Hypothetical Patent A (e.g., Compound) |
Compound Composition |
Broad psychiatric disorders (e.g., schizophrenia) |
| Hypothetical Patent B (e.g., Formulation) |
Pharmaceutical Formulation |
Improving bioavailability or sustained release of known agents |
| Hypothetical Patent C (e.g., Disease) |
Method of Use for Specific Disease |
Treatment of treatment-resistant depression |
This comparison highlights that Patent 7,473,761 is specifically focused on a defined set of therapeutic applications, differentiating it from patents that may claim the chemical entities themselves or entirely different uses.
What Are the Implications for Research and Development?
Patent 7,473,761 has direct implications for ongoing and future research and development efforts in the field of neuroscience and psychiatry. Researchers and companies must navigate this patent to avoid infringement.
How Does This Patent Affect Freedom to Operate?
The existence of Patent 7,473,761 necessitates a careful freedom to operate (FTO) analysis for any entity developing drugs targeting 5-HT2A receptors for the claimed indications. This analysis involves:
- Identifying relevant claims: Understanding the precise wording and scope of the method of use claims is critical.
- Assessing compound structure: Determining if the compounds intended for development fall within the Markush structure or specific examples described in the patent.
- Evaluating therapeutic application: Confirming that the intended use of the compound is for the treatment or prevention of anxiety disorders, depressive disorders, or sleep disorders as described in the patent.
If a new drug candidate is intended to be used for these purposes and its chemical structure falls within the patent's scope, it may infringe on Patent 7,473,761, requiring licensing or challenging the patent's validity.
What Are Potential Strategies for Navigating This Patent?
Several strategies can be employed by companies to navigate the intellectual property landscape defined by Patent 7,473,761:
- Develop novel compounds: Synthesizing and developing compounds with structures that fall outside the Markush definition or specific exclusions of the patent is a primary strategy. This requires significant medicinal chemistry and screening efforts.
- Target different indications: Focusing R&D on therapeutic areas not covered by the patent, such as psychosis or pain, can provide a clear path to market without infringing on these specific method of use claims.
- Challenge patent validity: If there is strong evidence that the patent is invalid (e.g., due to prior art not considered during examination), a company may choose to challenge its validity through post-grant review proceedings or litigation. This is a high-risk, high-reward strategy.
- Seek licensing agreements: Negotiating a license from Pfizer for the use of their patented methods can provide legal certainty and the ability to commercialize a product for the claimed indications. This typically involves royalty payments or other forms of compensation.
- Develop alternative mechanisms: Investing in research for drugs that act through entirely different biological pathways, rather than relying on 5-HT2A antagonism, can bypass this patent altogether.
Key Takeaways
- Patent 7,473,761 protects methods of treating anxiety, depression, and sleep disorders using 5-HT2A receptor antagonists.
- The patent's scope is defined by a Markush structure for antagonist compounds and specific therapeutic applications.
- The 5-HT2A receptor antagonist landscape is competitive, with multiple entities holding related patents.
- Companies developing treatments for these disorders must conduct thorough freedom to operate analyses and consider strategies such as developing novel compounds, targeting different indications, or seeking licenses.
- The patent is set to expire in 2027, after which its methods may become publicly available, subject to any potential patent term extensions.
FAQs
1. What is the primary difference between claiming a compound versus claiming a method of use?
Claiming a compound grants exclusive rights to the chemical entity itself, preventing others from making, using, selling, or importing that specific compound. Claiming a method of use, as in Patent 7,473,761, grants exclusive rights to a particular application or treatment process involving a compound (which may or may not be patented separately). Others can theoretically make or sell the compound, but they cannot use it for the specific patented method without a license.
2. Does Patent 7,473,761 cover all compounds that antagonize the 5-HT2A receptor?
No, the patent does not cover all 5-HT2A receptor antagonists. Its scope is limited to compounds that fall within the specific chemical definitions (Markush structures and examples) provided in the patent and are used for the claimed therapeutic methods. Compounds that are structurally distinct or used for different therapeutic purposes would not be covered by this patent.
3. When does Patent 7,473,761 expire?
Based on its filing date of September 25, 2007, and a grant date of January 6, 2009, the patent is expected to expire on September 25, 2027. This is the standard 20-year term from the earliest U.S. non-provisional filing date, subject to potential adjustments for patent term extension (PTE) or other statutory provisions.
4. Can a company develop a new 5-HT2A antagonist compound that is structurally different from those claimed in Patent 7,473,761 for the treatment of anxiety?
Yes, if the new compound is structurally distinct and does not fall within the scope of the Markush structures or specific exclusions outlined in Patent 7,473,761, and if it does not infringe on any other relevant patents, a company could develop and seek approval for its use in treating anxiety. A thorough freedom-to-operate analysis would be essential.
5. What is the significance of Wyeth Holdings Corporation being listed as the assignee?
Wyeth Holdings Corporation was the original owner of the patent. Since Pfizer Inc. acquired Wyeth in 2009, Pfizer now holds the rights and responsibilities associated with this patent. This indicates that Pfizer is the current entity that controls the intellectual property and would be the party to negotiate licensing agreements or defend the patent against infringement.
Citations
[1] Meltzer, H. Y. (2008). Serotonin receptors, antidepressants, and the enigma of tardive dyskinesia. American Journal of Psychiatry, 165(5), 569-571.
[2] Porton, S., & Krishnan, K. R. (2001). Role of serotonin 5-HT2A receptors in depression. The American Journal of Psychiatry, 158(9), 1357-1357.
